Amgen Inc (NASDAQ:AMGN) announced better-than-expected second-quarter results, raising its full-year forecast.
The pharmaceutical giant reported earnings late Thursday of US$3.83 per share on revenue of US$6.06bn compared with EPS of US$3.27 on revenue of US$5.81bn in the previous year’s second quarter.
The California-based company beat Wall Street estimates of US$3.52 EPS on revenue of $5.72bn.
For the year ahead, the company raised its earnings forecast to US$13.30 to US$14 from its previous guidance of US$12.80 to US$13.70.
READ: AstraZeneca plots a return to growth as cancer portfolio boosts first-half performance
Its revenue expectations were upped as well to US$22.5bn to US$23.2bn versus its previous estimate of US$21.9bn to US$22.8bn.
The drugmaker also vowed not to raise drug prices again this year, following the lead of other US companies like Novartis and Pfizer as well as European companies like Roche and Bayer.
The company is losing two executives, research chief Sean Harper and global commercial operations VP Tony Hooper.
Shares of Amgen were up around 1% to US$196 in Friday pre-market trading.